Literature DB >> 23159544

Morphine prevents the development of stress-enhanced fear learning.

Jennifer L Szczytkowski-Thomson1, Christina L Lebonville, Donald T Lysle.   

Abstract

The current study investigates the pharmacotherapeutic use of morphine as a preventative treatment for stress-enhanced fear learning, an animal model that closely mimics symptoms of post-traumatic stress disorder (PTSD). PTSD is a chronic and debilitating anxiety disorder characterized by exaggerated fear and/or anxiety that may develop as a result of exposure to a traumatic event. In this model, rats are exposed to a severe stressor (15 foot shocks) in one environment (Context A) and then subsequently exposed to a milder form of the same stressor (single foot shock) in a different environment (Context B). Animals that did not receive prior shock treatment exhibit fear responsiveness to Context B in line with the severity of the single shock given in this context. Animals that had received prior shock treatment in Context A exhibit an exaggerated learned fear response to Context B. Furthermore, animals receiving a single dose of morphine immediately following the severe stressor in Context A continue to show an enhanced fear response in Context B. However, animals receiving repeated morphine administration (three injections) after exposure to the severe stressor in Context A or a single dose of morphine at 48 h after the severe stressor no longer exhibit an enhancement in fear learning to Context B. These results are consistent with clinical studies suggesting that morphine treatment following a severe stressor may be useful in preventing or reducing the severity of PTSD in at-risk populations.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23159544     DOI: 10.1016/j.pbb.2012.10.013

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  16 in total

1.  Protective effects of the novel adenosine derivative WS0701 in a mouse model of posttraumatic stress disorder.

Authors:  Zhong-lin Huang; Rui Liu; Xiao-yu Bai; Gang Zhao; Jun-ke Song; Song Wu; Guan-hua Du
Journal:  Acta Pharmacol Sin       Date:  2013-12-16       Impact factor: 6.150

2.  The role of brain interleukin-1 in stress-enhanced fear learning.

Authors:  Meghan E Jones; Christina L Lebonville; Daniel Barrus; Donald T Lysle
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

Review 3.  Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Authors:  N Singewald; C Schmuckermair; N Whittle; A Holmes; K J Ressler
Journal:  Pharmacol Ther       Date:  2014-12-27       Impact factor: 12.310

Review 4.  Anesthesia and the neurobiology of fear and posttraumatic stress disorder.

Authors:  Keith M Vogt; Kane O Pryor
Journal:  Curr Opin Anaesthesiol       Date:  2022-08-19       Impact factor: 2.733

Review 5.  Dysfunctional Heteroreceptor Complexes as Novel Targets for the Treatment of Major Depressive and Anxiety Disorders.

Authors:  Miguel Pérez de la Mora; Dasiel O Borroto-Escuela; Minerva Crespo-Ramírez; José Del Carmen Rejón-Orantes; Daniel Alejandro Palacios-Lagunas; Magda K Martínez-Mata; Daniela Sánchez-Luna; Emiliano Tesoro-Cruz; Kjell Fuxe
Journal:  Cells       Date:  2022-06-02       Impact factor: 7.666

6.  Effects of acute pain medications on posttraumatic stress symptoms in early aftermath of trauma.

Authors:  Aaron S Grau; Hong Xie; Roberta E Redfern; Mohamad Moussa; Xin Wang; Chia-Hao Shih
Journal:  Int Clin Psychopharmacol       Date:  2022-05-02       Impact factor: 2.023

Review 7.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

Review 8.  An Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical Trials.

Authors:  Mallory E Bowers; Kerry J Ressler
Journal:  Biol Psychiatry       Date:  2015-06-15       Impact factor: 13.382

9.  Morphine administration during low ovarian hormone stage results in transient over expression of fear memories in females.

Authors:  Emily M Perez-Torres; Dinah L Ramos-Ortolaza; Roberto Morales; Edwin Santini; Efrain J Rios-Ruiz; Annelyn Torres-Reveron
Journal:  Front Behav Neurosci       Date:  2015-05-22       Impact factor: 3.558

10.  Hippocampal interleukin-1 mediates stress-enhanced fear learning: A potential role for astrocyte-derived interleukin-1β.

Authors:  Meghan E Jones; Christina L Lebonville; Jacqueline E Paniccia; Megan E Balentine; Kathryn J Reissner; Donald T Lysle
Journal:  Brain Behav Immun       Date:  2017-09-28       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.